CA2766876C - Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease - Google Patents
Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease Download PDFInfo
- Publication number
- CA2766876C CA2766876C CA2766876A CA2766876A CA2766876C CA 2766876 C CA2766876 C CA 2766876C CA 2766876 A CA2766876 A CA 2766876A CA 2766876 A CA2766876 A CA 2766876A CA 2766876 C CA2766876 C CA 2766876C
- Authority
- CA
- Canada
- Prior art keywords
- snp
- gene
- locus
- chromosome
- picalm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0911539A GB0911539D0 (en) | 2009-07-03 | 2009-07-03 | Diagnosis of alzheimer's disease |
| GB0911539.5 | 2009-07-03 | ||
| GB0913357.0 | 2009-07-31 | ||
| GB0913357A GB0913357D0 (en) | 2009-07-31 | 2009-07-31 | Diagnosis of alzheimer's disease |
| GB0917326.1 | 2009-10-03 | ||
| GB0917326A GB0917326D0 (en) | 2009-10-03 | 2009-10-03 | Diagnosis of alzheimer's disease |
| PCT/GB2010/001208 WO2011001135A2 (en) | 2009-07-03 | 2010-06-22 | Diagnosis and treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2766876A1 CA2766876A1 (en) | 2011-01-06 |
| CA2766876C true CA2766876C (en) | 2020-01-28 |
Family
ID=43014386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2766876A Active CA2766876C (en) | 2009-07-03 | 2010-06-22 | Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20120122703A1 (https=) |
| EP (2) | EP2891723B1 (https=) |
| JP (2) | JP5917395B2 (https=) |
| CN (2) | CN102471800A (https=) |
| AU (1) | AU2010267835C1 (https=) |
| CA (1) | CA2766876C (https=) |
| NZ (1) | NZ596614A (https=) |
| WO (1) | WO2011001135A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2766876C (en) * | 2009-07-03 | 2020-01-28 | University College Cardiff Consultants Limited | Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease |
| WO2011024035A1 (en) * | 2009-08-27 | 2011-03-03 | Institut Pasteur De Lille | Method for determining the risk of occurrence of alzheimer's disease |
| GB201212334D0 (en) * | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
| CN104102839B (zh) * | 2013-11-16 | 2017-10-27 | 西安电子科技大学 | 一种基于多尺度网格曲面形状特征的阿尔茨海默病脑皮层自动分类方法 |
| CN105969885A (zh) * | 2016-06-24 | 2016-09-28 | 江苏雄鸣医药科技有限公司 | 一种阿尔兹海默症的基因诊断试剂盒 |
| CN106978475A (zh) * | 2016-08-17 | 2017-07-25 | 上海易瑞生物科技有限公司 | 一种阿尔茨海默氏病易感基因检测分型试剂盒及其应用 |
| CN106290823A (zh) * | 2016-10-18 | 2017-01-04 | 上海凯璟生物科技有限公司 | 一种阿尔兹海默综合症标志物abca7检测试剂盒和制备方法 |
| US11725232B2 (en) * | 2016-10-31 | 2023-08-15 | The Hong Kong University Of Science And Technology | Compositions, methods and kits for detection of genetic variants for alzheimer's disease |
| US20210293794A1 (en) * | 2017-02-24 | 2021-09-23 | University Of Hawii Cancer Center | Metabolic biomarkers for the identification and characterization of alzheimers disease |
| KR101933847B1 (ko) | 2017-05-15 | 2018-12-28 | 조선대학교산학협력단 | 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도 |
| WO2018212371A1 (ko) * | 2017-05-17 | 2018-11-22 | 조선대학교산학협력단 | 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도 |
| JP7399465B2 (ja) * | 2017-05-15 | 2023-12-18 | インフォメディテック・カンパニー，リミテッド | アルツハイマー病の危険性と関連するａｐｏｅプロモーターの一塩基多型およびその使用 |
| WO2019178167A1 (en) * | 2018-03-13 | 2019-09-19 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| EP3794345B1 (en) * | 2018-05-18 | 2025-02-26 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| CN110607364B (zh) * | 2019-11-01 | 2023-04-28 | 北京中医药大学 | 通过检测snp位点确定等位基因的基因型的方法 |
| KR102561438B1 (ko) * | 2020-11-04 | 2023-07-28 | 사회복지법인 삼성생명공익재단 | 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법 |
| JP7731540B2 (ja) * | 2021-03-26 | 2025-09-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット |
| US20240203524A1 (en) * | 2021-04-13 | 2024-06-20 | Kyoto University | Information processing method, information processing device, and storage medium |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| KR102775636B1 (ko) * | 2022-03-15 | 2025-03-05 | 사회복지법인 삼성생명공익재단 | 유럽 인구 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법 |
| CN114736963B (zh) * | 2022-05-25 | 2023-03-24 | 首都医科大学宣武医院 | 一种用于预测阿尔茨海默病发病风险的物质的组合、试剂盒及应用 |
| US12518859B2 (en) * | 2023-07-26 | 2026-01-06 | Helix, Inc. | Systems and methods for providing test results of gene sequencing data on a recurring basis |
| KR102940935B1 (ko) * | 2024-02-15 | 2026-03-17 | 이화여자대학교 산학협력단 | 고인지예비능 생체표지자로서의 snp 및 이의 이용 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2765591B1 (fr) * | 1997-07-01 | 2002-08-09 | Pasteur Institut | Procede de diagnostic de la maladie d'alzheimer |
| WO2006138716A2 (en) * | 2005-06-17 | 2006-12-28 | Brt Laboratories, Inc. | Thermodynamically defined gene specific primers |
| JP2007166962A (ja) * | 2005-12-21 | 2007-07-05 | Japan Health Science Foundation | アルツハイマー病の予測または診断の方法 |
| EP2082343A2 (en) * | 2006-11-02 | 2009-07-29 | Genizon Biosciences Inc. | Genemap of the human genes associated with asthma disease |
| SG177960A1 (en) * | 2007-04-17 | 2012-02-28 | Santen Pharmaceutical Co Ltd | Method for determination of onset risk of glaucoma |
| CA2766876C (en) * | 2009-07-03 | 2020-01-28 | University College Cardiff Consultants Limited | Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease |
-
2010
- 2010-06-22 CA CA2766876A patent/CA2766876C/en active Active
- 2010-06-22 CN CN2010800292599A patent/CN102471800A/zh active Pending
- 2010-06-22 JP JP2012516841A patent/JP5917395B2/ja active Active
- 2010-06-22 US US13/376,485 patent/US20120122703A1/en not_active Abandoned
- 2010-06-22 AU AU2010267835A patent/AU2010267835C1/en not_active Ceased
- 2010-06-22 EP EP15152097.0A patent/EP2891723B1/en not_active Not-in-force
- 2010-06-22 WO PCT/GB2010/001208 patent/WO2011001135A2/en not_active Ceased
- 2010-06-22 EP EP10747062.7A patent/EP2449134B1/en not_active Not-in-force
- 2010-06-22 NZ NZ59661410A patent/NZ596614A/xx unknown
- 2010-06-22 CN CN2013102808899A patent/CN103409511A/zh active Pending
-
2013
- 2013-05-03 US US13/886,473 patent/US20130288906A1/en not_active Abandoned
- 2013-08-07 JP JP2013164509A patent/JP5917460B2/ja active Active
-
2014
- 2014-04-14 US US14/252,153 patent/US20150119264A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2891723A1 (en) | 2015-07-08 |
| US20130288906A1 (en) | 2013-10-31 |
| NZ596614A (en) | 2012-11-30 |
| JP2014012007A (ja) | 2014-01-23 |
| HK1169455A1 (en) | 2013-01-25 |
| EP2891723B1 (en) | 2017-10-04 |
| JP2012531195A (ja) | 2012-12-10 |
| AU2010267835B2 (en) | 2014-11-06 |
| JP5917395B2 (ja) | 2016-05-11 |
| US20120122703A1 (en) | 2012-05-17 |
| CA2766876A1 (en) | 2011-01-06 |
| EP2449134B1 (en) | 2016-07-27 |
| US20150119264A1 (en) | 2015-04-30 |
| CN103409511A (zh) | 2013-11-27 |
| EP2449134A2 (en) | 2012-05-09 |
| WO2011001135A3 (en) | 2011-06-30 |
| JP5917460B2 (ja) | 2016-05-18 |
| WO2011001135A9 (en) | 2011-02-24 |
| CN102471800A (zh) | 2012-05-23 |
| WO2011001135A2 (en) | 2011-01-06 |
| AU2010267835C1 (en) | 2015-02-26 |
| AU2010267835A1 (en) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2766876C (en) | Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease | |
| CA2275504C (en) | Pharmacogenetic methods for use in the treatment of nervous system diseases | |
| CN103930568A (zh) | 用于治疗、诊断和监测阿尔茨海默病的方法 | |
| Vladutiu et al. | Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies | |
| Gaj et al. | Identification of a late onset Alzheimer's disease candidate risk variant at 9q21. 33 in Polish patients | |
| US20150044239A1 (en) | Compositions and Methods for Diagnosing, Preventing and Treating Intracranial Aneurysms | |
| AU2014265063B2 (en) | Diagnosis and treatment of Alzheimer's disease | |
| US9127316B2 (en) | Markers associated with Alzheimer'S disease | |
| AU2008242625A1 (en) | Methods of diagnosing Alzheimer's disease and markers identified by set association | |
| AU2013201440B2 (en) | Markers related to age-related macular degeneration and uses therefor | |
| US7842455B2 (en) | Susceptibility gene for Alzheimer's disease | |
| HK1169455B (en) | Diagnosis and treatment of alzheimer's disease | |
| US20140288011A1 (en) | Genetic association | |
| EP2894229A1 (en) | Markers related to age-related macular degeneration and uses therefor | |
| EP2603606B1 (en) | Methods and kits for of identifying a premature infant at risk of having or developing bronchopulmonary dysplasia | |
| Panitch | Understanding the mechanisms and pathways of Alzheimer’s disease in APOE genotype sub-populations | |
| US20120289593A1 (en) | Methods for risk assessment, treating, and diagnosing myocardial infarction | |
| WO2015082721A1 (en) | MEANS AND METHODS FOR ESTABLISHING A CLINICAL PROGNOSIS OF DISEASES ASSOCIATED WITH THE FORMATION OF AGGREGATES OF Aβ1-42 | |
| JP2022150707A (ja) | アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251020 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |